Canocapavir

Canocapavir
Clinical data
Other names	ZM-H1505R
Legal status
Legal status	investigational;
Identifiers
	IUPAC name (2R)-2-[1-(4-bromophenyl)-3-(4-fluorophenyl)pyrazol-4-yl]-3-[2-(2-oxo-1,3-dihydrobenzimidazol-5-yl)ethyl]-1,3-oxazolidin-4-one;
CAS Number	2137847-19-7;
PubChem CID	137477479;
DrugBank	DB21570;
ChemSpider	128921743;
UNII	ITF8H4SZR1;
ChEBI	CHEBI:758676;
ChEMBL	ChEMBL5095093;
Chemical and physical data
Formula	C27H21BrFN5O3
Molar mass	562.399 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C(=O)N([C@H](O1)C2=CN(N=C2C3=CC=C(C=C3)F)C4=CC=C(C=C4)Br)CCC5=CC6=C(C=C5)NC(=O)N6;
	InChI InChI=InChI=1S/C27H21BrFN5O3/c28-18-4-8-20(9-5-18)34-14-21(25(32-34)17-2-6-19(29)7-3-17)26-33(24(35)15-37-26)12-11-16-1-10-22-23(13-16)31-27(36)30-22/h1-10,13-14,26H,11-12,15H2,(H2,30,31,36)/t26-/m1/s1; Key:YGPZZDKSASSELG-AREMUKBSSA-N;

Canocapavir is an investigational new drug that is being evaluated by Zhimeng Biopharma for the treatment of Hepatitis B infections.^[1] It is an HBV capsid assembly inhibitor.^[2]^[3]^[4]

Clinical trials

Phase 3 clinical trials of canocapavir for the treatment of chronic HBV infections are planned.^[5]

References

↑ "Canocapavir - Zhimeng Biopharma". AdisInsight. Springer Nature Switzerland AG.
↑ Zheng Y, Yang L, Yu L, Zhu Y, Wu Y, Zhang Z, et al. (May 2023). "Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein". Viruses. 15 (5): 1195. doi:10.3390/v15051195. PMC 10223407. PMID 37243280.
↑ McFadden WM, Sarafianos SG (August 2023). "Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure". Global Health & Medicine. 5 (4) 2023.01065: 199–207. doi:10.35772/ghm.2023.01065. PMC 10461335. PMID 37655181.
↑ Zhu C, Yang J, Sheng Y, Fang M (2026). "Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease". Frontiers in Immunology. 17 1806527. doi:10.3389/fimmu.2026.1806527. PMC 13222988. PMID 42233029.
↑ Clinical trial number NCT07095855 for "A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB" at ClinicalTrials.gov

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

[AdisInsight-1] "Canocapavir - Zhimeng Biopharma". AdisInsight. Springer Nature Switzerland AG.

[Zheng_2023-2] Zheng Y, Yang L, Yu L, Zhu Y, Wu Y, Zhang Z, et al. (May 2023). "Canocapavir Is a Novel Capsid Assembly Modulator Inducing a Conformational Change of the Linker Region of HBV Core Protein". Viruses. 15 (5): 1195. doi:10.3390/v15051195. PMC 10223407. PMID 37243280.

[McFadden_2023-3] McFadden WM, Sarafianos SG (August 2023). "Biology of the hepatitis B virus (HBV) core and capsid assembly modulators (CAMs) for chronic hepatitis B (CHB) cure". Global Health & Medicine. 5 (4) 2023.01065: 199–207. doi:10.35772/ghm.2023.01065. PMC 10461335. PMID 37655181.

[Zhu_2026-4] Zhu C, Yang J, Sheng Y, Fang M (2026). "Emerging antiviral drugs and immunotherapy for chronic hepatitis B and associated liver disease". Frontiers in Immunology. 17 1806527. doi:10.3389/fimmu.2026.1806527. PMC 13222988. PMID 42233029.

[5] Clinical trial number NCT07095855 for "A Phase III Study to Evaluate the Efficacy and Safety of ZM-H1505R in Patients With CHB" at ClinicalTrials.gov

[1]

[2]

[3]

[4]

[5]

This page was redesigned at the edge.

Canocapavir

Clinical trials

See also

References